Alvine Pharmaceuticals

Alvine Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing therapeutics for autoimmune and gastrointestinal diseases, with a particular emphasis on celiac disease. The company's lead product candidate, ALV003, is an orally administered mixture of two gluten-specific proteases designed to degrade gluten, the primary immunologic trigger for celiac disease. In addition to ALV003, Alvine is working on proteases that target other aspects of celiac disease, including Transglutaminase 2 (TG2) and the HLA-DQ2 antigen. Founded in 2005 and based in San Carlos, California, Alvine Pharmaceuticals operates as a subsidiary of ImmunogenX, LLC as of February 2016.